Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.

In a pre-planned CALLA correlative analysis, Personalis NeXT Personal detected ctDNA in 183/185 (98.9%) baseline samples; post-CRT (C3D1) ctDNA detection preceded clinical progression by a median of 164 days (95% CI 85–250), and lower-than-median baseline ctDNA was associated with better PFS in the CRT arm (HR 0.49, 95% CI 0.26–0.95).

Annals of OncologyPubMed 40500687DOI 10.1016/j.annonc.2025.05.533